Keytruda and PD-L1: a Real-World Example of Co-development of a Drug with a Predictive Biomarker.

The AAPS Journal
Kenneth Emancipator

Abstract

Pembrolizumab, an anti-programmed death 1 monoclonal antibody, underwent a rapid clinical development program for the treatment of patients with malignancies in parallel to the development of a companion diagnostic for detecting programmed death ligand 1 (PD-L1) expression, which was considered to be a likely biomarker for response and cancer outcome. When investigating outcomes in patients with non-small cell lung cancer (NSCLC) treated with pembrolizumab, PD-L1 tumor proportion score (TPS) was initially identified as a marker of clinical efficacy, with a cutoff of ≥ 50%. This threshold was later reduced to TPS ≥ 1%, which demonstrated that pembrolizumab offered a clinical benefit in a broader population of patients with PD-L1-expressing tumors. As new evidence emerged, it also became clear that immune cell PD-L1 expression has an important role in predicting tumor response in patients treated with pembrolizumab; the combined positive score (CPS), which accounts for both tumor and immune cell PD-L1 expression, was then applied in clinical studies for indications outside of NSCLC. This review summarizes the outcomes of landmark studies in the KEYNOTE clinical development program that investigated the efficacy of pembrolizumab i...Continue Reading

References

Mar 17, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Richard L SchilskyBarbara A Conley
Apr 22, 2015·The New England Journal of Medicine·Edward B GaronUNKNOWN KEYNOTE-001 Investigators
Jun 23, 2016·Applied Immunohistochemistry & Molecular Morphology : AIMM·Charlotte RoachKarina Kulangara
Aug 24, 2016·Archives of Pathology & Laboratory Medicine·Marisa Dolled-FilhartKenneth Emancipator
Oct 11, 2016·The New England Journal of Medicine·Martin ReckUNKNOWN KEYNOTE-024 Investigators
Dec 4, 2016·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Fred R HirschKeith M Kerr
Feb 18, 2017·The New England Journal of Medicine·Joaquim BellmuntUNKNOWN KEYNOTE-045 Investigators
Apr 17, 2018·The New England Journal of Medicine·Leena GandhiUNKNOWN KEYNOTE-189 Investigators
May 26, 2018·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Ming Sound TsaoFred R Hirsch
Oct 10, 2018·Proceedings of the National Academy of Sciences of the United States of America·Marcin KowanetzPriti S Hegde
Nov 1, 2018·Oncoimmunology·Jeremiah L OyerAlicja J Copik
Dec 18, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Patrick A OttJared K Lunceford
Jan 19, 2019·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R S HerbstE B Garon
Apr 4, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hyun Cheol ChungAlexandra Leary
Jan 29, 2020·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R S HerbstE B Garon
Feb 23, 2020·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J MetgesT Doi

❮ Previous
Next ❯

Citations

Jan 29, 2021·Viruses·Kazuya Nagano, Yasuo Tsutsumi
May 1, 2021·Cancers·Mattia GaruttiFabio Puglisi
May 15, 2021·EMBO Molecular Medicine·Devadarssen MurdamoothooGertraud Orend
Aug 25, 2021·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Tracy L RoseMatthew I Milowsky

❮ Previous
Next ❯

Methods Mentioned

BETA
Assay

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.